348 related articles for article (PubMed ID: 9759593)
21. Circulating D dimer in inflammatory bowel disease.
Biancone L; Scopinaro F; Maletta M; Monteleone G; Luzza F; Banci M; Mercantini P; Renda T; Pallone F
Ital J Gastroenterol; 1994 Apr; 26(3):116-20. PubMed ID: 8061337
[TBL] [Abstract][Full Text] [Related]
22. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
[TBL] [Abstract][Full Text] [Related]
23. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease.
Cakal B; Gokmen A; Yalinkilic M; Cakal E; Ayaz S; Nadir I; Ozin Y; Dagli U; Ulker A
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):118-21. PubMed ID: 20040858
[TBL] [Abstract][Full Text] [Related]
24. [Familial prevalence in chronic intestinal inflammatory disease. Differences among groups of patients with and without a familial history].
Nos P; Argüello L; Hoyos M; Ramírez JJ; Hinojosa J; Molés JR; García A; Berenguer M; Berenguer J
Rev Esp Enferm Dig; 1996 Jul; 88(7):470-4. PubMed ID: 8924324
[TBL] [Abstract][Full Text] [Related]
25. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
[TBL] [Abstract][Full Text] [Related]
26. Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease.
Hocke M; Richter L; Bosseckert H; Eitner K
Hepatogastroenterology; 1999; 46(28):2333-7. PubMed ID: 10521992
[TBL] [Abstract][Full Text] [Related]
27. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases.
Jung YS; Park JJ; Kim SW; Hong SP; Kim TI; Kim WH; Cheon JH
Dig Liver Dis; 2012 Nov; 44(11):897-903. PubMed ID: 22721842
[TBL] [Abstract][Full Text] [Related]
28. Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice?
Candelli M; Papa A; Nista EC; Danese S; Armuzzi A; Bartolozzi F; Tondi P; Ojetti V; Gasbarrini G; Gasbarrini A
Hepatogastroenterology; 2003; 50(51):718-20. PubMed ID: 12828069
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.
Naftali T; Novick D; Gabay G; Rubinstein M; Novis B
Isr Med Assoc J; 2007 Jul; 9(7):504-8. PubMed ID: 17710779
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996.
Torres EA; De Jesús R; Pérez CM; Iñesta M; Torres D; Morell C; Just E
P R Health Sci J; 2003 Sep; 22(3):253-8. PubMed ID: 14619451
[TBL] [Abstract][Full Text] [Related]
31. High plasma osteopontin levels in patients with inflammatory bowel disease.
Mishima R; Takeshima F; Sawai T; Ohba K; Ohnita K; Isomoto H; Omagari K; Mizuta Y; Ozono Y; Kohno S
J Clin Gastroenterol; 2007 Feb; 41(2):167-72. PubMed ID: 17245215
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil-elastase in chronic inflammatory bowel disease: a marker of disease activity?
Gouni-Berthold I; Baumeister B; Wegel E; Berthold HK; Vetter H; Schmidt C
Hepatogastroenterology; 1999; 46(28):2315-20. PubMed ID: 10521989
[TBL] [Abstract][Full Text] [Related]
33. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
Dotan I; Fishman S; Dgani Y; Schwartz M; Karban A; Lerner A; Weishauss O; Spector L; Shtevi A; Altstock RT; Dotan N; Halpern Z
Gastroenterology; 2006 Aug; 131(2):366-78. PubMed ID: 16890590
[TBL] [Abstract][Full Text] [Related]
34. Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events.
Papa A; Danese S; Piccirillo N; Toriani-Terenzi C; Bartolozzi F; Piscaglia AC; Grillo A; Leone G; Gentiloni-Silveri N; Gasbarrini G; Gasbarrini A
Hepatogastroenterology; 2003; 50(49):132-5. PubMed ID: 12630008
[TBL] [Abstract][Full Text] [Related]
35. Defense mechanisms in inflammatory bowel disease.
Hyphantis TN; Triantafillidis JK; Pappa S; Mantas C; Kaltsouda A; Cherakakis P; Alamanos Y; Manousos ON; Mavreas VG
J Gastroenterol; 2005 Jan; 40(1):24-30. PubMed ID: 15692786
[TBL] [Abstract][Full Text] [Related]
36. Serum gastrin levels in patients with inflammatory bowel disease.
Triantafillidis JK; Tzourmakliotis D; Peros G; Merikas E; Barbatzas C; Cheracakis P; Gikas A; Konstandellou E
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cccxv-cccxvii. PubMed ID: 15244213
[TBL] [Abstract][Full Text] [Related]
37. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation.
Kanazawa S; Tsunoda T; Onuma E; Majima T; Kagiyama M; Kikuchi K
Am J Gastroenterol; 2001 Mar; 96(3):822-8. PubMed ID: 11280558
[TBL] [Abstract][Full Text] [Related]
38. Resistin is an inflammatory marker of inflammatory bowel disease in humans.
Konrad A; Lehrke M; Schachinger V; Seibold F; Stark R; Ochsenkühn T; Parhofer KG; Göke B; Broedl UC
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831
[TBL] [Abstract][Full Text] [Related]
39. The disease activity of ulcerative colitis and Crohn's disease.
Talstad I; Gjone E
Scand J Gastroenterol; 1976; 11(4):403-8. PubMed ID: 935802
[TBL] [Abstract][Full Text] [Related]
40. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
